[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,075,622
  • Shares Outstanding, K 110,373
  • Annual Sales, $ 11,035 M
  • Annual Income, $ 992,000 K
  • EBIT $ 1,781 M
  • EBITDA $ 2,351 M
  • 60-Month Beta 0.56
  • Price/Sales 2.36
  • Price/Cash Flow 15.45
  • Price/Book 3.31

Options Overview Details

View History
  • Implied Volatility 19.75% (-0.47%)
  • Historical Volatility 28.68%
  • IV Percentile 5%
  • IV Rank 10.88%
  • IV High 39.24% on 07/22/26
  • IV Low 17.37% on 08/19/25
  • Expected Move (DTE 2) 4.17 (1.76%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 80
  • Volume Avg (30-Day) 704
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 14,062
  • Open Int (30-Day) 11,779
  • Expected Range 231.94 to 240.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.85
  • Number of Estimates 8
  • High Estimate $2.90
  • Low Estimate $2.82
  • Prior Year $2.60
  • Growth Rate Est. (year over year) +9.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
204.10 +17.66%
on 07/21/26
240.85 -0.29%
on 08/19/26
+29.47 (+13.99%)
since 07/17/26
3-Month
188.88 +27.15%
on 05/21/26
240.85 -0.29%
on 08/19/26
+49.76 (+26.14%)
since 05/19/26
52-Week
171.18 +40.30%
on 01/05/26
240.85 -0.29%
on 08/19/26
+57.32 (+31.35%)
since 08/19/25

Most Recent Stories

More News
Digi Power X Reports Second Quarter 2026 Financial Results and Provides Operational Update and 2027 Outlook

Highlights $1.1 Billion of Contracted AI Infrastructure Revenue, First AI Compute Revenue, Positive Adjusted EBITDA and Strong Balance Sheet

DGX : 240.64 (+1.86%)
DGX.NE : 4.8000 (-4.38%)
DGX.VN : 3.790 (+5.28%)
DGXX : 3.44 (-3.91%)
Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J. , Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash...

DGX : 240.64 (+1.86%)
Digi Power X to Announce 2026 Q2 Financial Results and Provide Operations Update on August 14th

MIAMI, FL / ACCESS Newswire / August 4, 2026 / Digi Power X Inc. (NASDAQ:DGXX)(Cboe Canada:DGX) (the "Company" or "Digi Power X"), an AI data center infrastructure operator, plans to announce its financial...

DGX : 240.64 (+1.86%)
DGX.NE : 4.8000 (-4.38%)
DGX.VN : 3.790 (+5.28%)
DGXX : 3.44 (-3.91%)
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics

Largest nationally representative study finds 12% of patients positive for bacterial vaginosis are infected with at least one STI, such as chlamydia or gonorrhea

DGX : 240.64 (+1.86%)
Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars

Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars

DGX : 240.64 (+1.86%)
Quest Diagnostics: Q2 Earnings Snapshot

Quest Diagnostics: Q2 Earnings Snapshot

DGX : 240.64 (+1.86%)
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

SECAUCUS, N.J. , July 23, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second...

DGX : 240.64 (+1.86%)
Quest Diagnostics Reports Earnings the Same Day It Pays Shareholders Their Quarterly Dividend

Barchart Research What to Expect from DGX Earnings DGX Generated July 22, 2026 Current Price $209.83 EPS Estimate $$2.81 Consensus Rating Moderate Buy Average Move 5.69% Quest Diagnostics Reports Earnings...

DGX : 240.64 (+1.86%)
One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

SECAUCUS, N.J. , July 10, 2026 /PRNewswire/ -- Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis of hair specimens collected in 2025,...

DGX : 240.64 (+1.86%)
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD

DGX : 240.64 (+1.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services...

See More

Key Turning Points

3rd Resistance Point 241.71
2nd Resistance Point 240.54
1st Resistance Point 238.40
Last Price 240.64
1st Support Level 235.09
2nd Support Level 233.92
3rd Support Level 231.78

See More

52-Week High 240.85
Last Price 240.64
Fibonacci 61.8% 214.23
Fibonacci 50% 206.01
Fibonacci 38.2% 197.79
52-Week Low 171.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.